Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin

A short half-life in the circulation limits the application of therapeutics such as single-domain antibodies (VHHs). We utilize red blood cells to prolong the circulatory half-life of VHHs. Here we present VHHs against botulinum neurotoxin A (BoNT/A) on the surface of red blood cells by expressing c...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Nai-Jia, Pishesha, Novalia, Mukherjee, Jean, Zhang, Sicai, Deshycka, Rhogerry, Sudaryo, Valentino, Dong, Min, Shoemaker, Charles B., Lodish, Harvey F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583347/
https://www.ncbi.nlm.nih.gov/pubmed/28871080
http://dx.doi.org/10.1038/s41467-017-00448-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583347/
https://www.ncbi.nlm.nih.gov/pubmed/28871080
http://dx.doi.org/10.1038/s41467-017-00448-0

Ejemplares similares